Showing 1451-1460 of 1808 results for "".
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20
- VelaShape III Platform from Syneron Receives FDA Clearance for Abdominal Circumferential Reductionhttps://practicaldermatology.com/news/20130911-synerons_velashape_iii_platform_receives_fda_clearance_for_abdominal_circumferential_reduction/2459464/The VelaShape III, Syneron's new non-invasive body shaping platform, recently received FDA clearance and CE mark approval for temporary reduction in circumference of the abdomen. The VelaShape III
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Bimekizumab Shown Safe at 3 Years for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/bimekizumab-shown-safe-at-3-years-for-moderate-to-severe-plaque-psoriasis/2462216/In a poster presented at Maui Derm, 2024, results from a long-term pooled analysis from five phase-3/3b trials indicate that bimekizumab (BKZ) is safe and well-tolerated at the 3-year mark in patients with moderate-to-s